Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2821-2825

  Silva, J M ^a   Dominguez, G ^a   Silva, J ^a   Garcia, J M ^a   Sanchez, A ^a   Rodriguez, O ^a   Provencio, M ^a   Espana P ^a   Bonilla, F ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ACTINS; BREAST NEOPLASMS; EPITHELIUM; FEMALE; HUMANS; KERATINS; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UTEROGLOBIN;

EID: 0034812729     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cancer statistics
2. Long-term cancer patient survival in the United States
3. Breast cancer
4. Microsatellite alterations in plasma DNA of small cell lung cancer patients
5. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
6. Microsatellite alterations and TP53 mutations in plasma DNA of small cell lung cancer patients: Follow-up study and prognostic significance
7. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations
8. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer
9. Microsatellite abnormalities in plasma of patients with breast carcinoma: Concordance with the primary tumor
10. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
11. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer
12. Molecular detection of genetic alterations in serum of colorectal cancer patients
13. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance
14. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
15. Electrophoretic characterization of plasma RNA
16. An "external" RNA removable from mammalian cells by mild proteolysis
17. Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: First clinical evaluation of a novel tumor marker
18. Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans
19. Circulating membrane vesicles in leukemic blood
20. Detection of tumor messenger RNA in the serum of patients with malignant melanoma
21. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma
22. Telomerase RNA as a detection marker in the serum of breast cancer patients
23. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease
24. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease
25. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus
26. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma
27. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumors
28. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen
29. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients
30. Utilization of polymerase chain reaction technology in the detection of solid tumors
31. Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (Esb)
32. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer